MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects

Phase 1
Terminated
Conditions
Elderly, Frail
Interventions
Procedure: Vitamin D Placebo + Exercise
Procedure: Vitamin D Placebo + Sham Exercise
Drug: Vitamin D + Sham Exercise
Drug: Vitamin D + Exercise
First Posted Date
2005-11-07
Last Posted Date
2009-01-08
Lead Sponsor
Pfizer
Target Recruit Count
64
Registration Number
NCT00249704
Locations
🇺🇸

Pfizer Investigational Site, New York, New York, United States

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

Phase 2
Completed
Conditions
Liver Neoplasms
Unresectable Hepatocellular Carcinoma
Interventions
First Posted Date
2005-11-02
Last Posted Date
2010-02-18
Lead Sponsor
Pfizer
Target Recruit Count
37
Registration Number
NCT00247676
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

US Inhaled Insulin Dose Titration Study

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2005-10-30
Last Posted Date
2008-02-08
Lead Sponsor
Pfizer
Target Recruit Count
120
Registration Number
NCT00246623
Locations
🇺🇸

Pfizer Investigational Site, Bennington, Vermont, United States

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
Drug: Chemotherapy
First Posted Date
2005-10-30
Last Posted Date
2012-07-12
Lead Sponsor
Pfizer
Target Recruit Count
217
Registration Number
NCT00246571
Locations
🇬🇧

Pfizer Investigational Site, Southampton, United Kingdom

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Phase 4
Completed
Conditions
HIV Infection
Interventions
First Posted Date
2005-10-30
Last Posted Date
2011-04-28
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT00246610
Locations
🇨🇦

Pfizer Investigational Site, Toronto, Ontario, Canada

S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation

Phase 3
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2005-10-26
Last Posted Date
2018-12-19
Lead Sponsor
Pfizer
Target Recruit Count
1372
Registration Number
NCT00244426
Locations
🇮🇹

Pfizer Investigational Site, Viterbo, Italy

Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
Drug: SU011248/Trastuzumab
First Posted Date
2005-10-24
Last Posted Date
2011-07-22
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT00243503
Locations
🇪🇸

Pfizer Investigational Site, Valencia, Spain

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Phase 3
Completed
Conditions
Endometrial Hyperplasia
Osteoporosis
Interventions
Other: Placebo
Drug: Bazedoxifene/Conjugated Estrogen
Drug: CE 0.45 mg/MPA 1.5mg
First Posted Date
2005-10-20
Last Posted Date
2013-12-20
Lead Sponsor
Pfizer
Target Recruit Count
1083
Registration Number
NCT00242710
Locations
🇺🇸

Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States

Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Phase 3
Terminated
Conditions
Gram-Positive Bacterial Infections
First Posted Date
2005-10-18
Last Posted Date
2012-05-25
Lead Sponsor
Pfizer
Registration Number
NCT00240747
Locations
🇺🇸

Children's Hospital, Cincinnati, Ohio, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Phase 2
Completed
Conditions
Macular Degeneration
Interventions
First Posted Date
2005-10-17
Last Posted Date
2011-05-12
Lead Sponsor
Pfizer
Target Recruit Count
61
Registration Number
NCT00239928
Locations
🇯🇵

Pfizer Investigational Site, Kyoto, Japan

© Copyright 2025. All Rights Reserved by MedPath